Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT01254565 is registered in ClinicalTrials.gov with KAI Pharmaceuticals as lead sponsor.

NCT NCT01254565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01254565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Lead sponsor
KAI Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 20, 2011
Completion date
August 24, 2011
Enrollment
87 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism